Amuvatinib

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameAmuvatinib
Drug Alias NameamuvatinibumHPK-56MP-470
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHepatocyte growth factor receptor inhibitorsDNA repair inhibitorsPlatelet-derived growth factor receptor alpha inhibitors +[6] 
TargetsStem cell growth factor receptorDNA repair protein RAD51 homolog 1Tyrosine-protein kinase receptor FLT3 +[5] 
Therapy Area/IndicationsSolid tumoursSmall Cell Lung CarcinomaNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesPoland
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAstex Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAstex Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsSolid tumoursSmall Cell Lung CarcinomaNeoplasms

Other Information

ATC CodeN/A
Related LinksKEGG